Patents by Inventor Andrew T. Watts

Andrew T. Watts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of tumor necrosis factor receptor 2 expression
    Patent number: 6410324
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Tumor Necrosis Factor Receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Tumor Necrosis Factor Receptor 2. Methods of using these compounds for modulation of Tumor Necrosis Factor Receptor 2 expression and for treatment of diseases associated with expression of Tumor Necrosis Factor Receptor 2 are provided.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: June 25, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Antisense modulation of phospholipase A2, group VI (Ca2+-independent) expression
    Patent number: 6410325
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2, group VI (Ca2+-independent). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2, group VI (Ca2+-independent). Methods of using these compounds for modulation of Phospholipase A2, group VI (Ca2+-independent) expression and for treatment of diseases associated with expression of Phospholipase A2, group VI (Ca2+-independent) are provided.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: June 25, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Andrew T. Watt
  • Antisense modulation of RECQL2 expression
    Patent number: 6399378
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL2. Methods of using these compounds for modulation of RECQL2 expression and for treatment of diseases associated with expression of RECQL2 are provided.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: June 4, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt